Industry Research

  1. What Are The Most Common Site Start-Up Strategies?

    ISR asked respondents at sponsor organizations, CROs, and site management organizations (SMOs) about a variety of start-up strategies and how frequently each is employed at their company.

  2. How Does Biopharma Outsource Clinical Logistics?

    In a recent survey targeting companies that outsource clinical logistics, ISR asked respondents to indicate the proportion of clinical services they have outsourced in the past year and what they estimate the proportion will look like in three years.

  3. mHealth Implementation — Use By Therapeutic Area

    While pharma companies, biotechs, and CROs are expanding their use of mHealth technologies, they are not expanding the use of it evenly across all therapeutic areas.

  4. What To Prioritize When Selecting A Phase 1 CRO

    A critical factor when examining service provider selection is the existence of preferred provider agreements. Keeping this in mind, ISR asks respondents to share their selection criteria in a way that demonstrates these agreements’ impacts on the decision-making process.

  5. The Most Important Oral Dose Life Cycle Extension Strategies

    For companies considering life cycle extension strategies for their oral-dose products, there are clear preferences as to which strategies they would pursue.

  6. Improving Outsourcing Relationships

    ISR research indicates that proactive communication between sponsors and CMOs in these three areas will help to improve outsourcing relationships. Data comes from ISR’s Development and Commercial Outsourcing Models market research report.

  7. Trends In Phase 4 CRO Selection Drivers

    As part of our yearly service provider quality benchmarking, Industry Standard Research asks late-phase decision makers to select their top five most important attributes when outsourcing with no preferred providers.

  8. Outsourcing Motivations Should Guide One’s Outsourcing Approach

    Outsourcing motivations are important considerations to identifying the best outsourcing approach and should influence the type of relationships your organization develops with CMOs. Data comes from ISR’s CMO Quality Benchmarking suite of market research reports and ISR’s Development and Commercial Outsourcing Models market research report.

  9. Influence Of Size In CRO Selection

    ISR surveyed hundreds of clinical development outsourcers about what they consider important when selecting providers. To capture the increasing role that preferred provider agreements are playing in the selection process, respondents were asked about attribute importance in several scenarios.

  10. How Prevalent Are PPAs In Phase 2/3 Research?

    Almost half of survey respondents report their companies use formal preferred provider agreements (PPAs) for their Phase 2/3 outsourcing.